Canaccord analyst John Newman raised the firm’s price target on Atara Biotherapeutics (ATRA) to $21 from $13 and keeps a Buy rating on the shares. The firm said its target increase is based on its expectations for positive ATA3219 data in NHL and Lupus in early 2025.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks